1 of 1
Story summary
- The China Securities Regulatory Commission (CSRC) tightens rules for US dollar-denominated funds investing in tech and biotech.
- David Lau of JPMorgan Chase notes that many Chinese firms prefer “red-chip-structured” arrangements for flexibility and to incentivize overseas employees.
- Regulators will oversee asset sales, and approved applicants must provide detailed foreign exchange and investment disclosures.
